Asia
Vela Diagnostics Submitting Novel Coronavirus Diagnostic Test to FDA for Emergency Use Authorization
Vela Diagnostics has developed the ViroKeyTM SA201 COVID-19 RT-PCR Test, a new diagnostic test for the detection of the COVID-19 coronavirus. Vela Diagnostics is currently in discussions with the U.S. Food and Drug Administration for clearance of the test under the emergency use authorization.
There is a significant amount of work being done on cardiovascular diseases. Here’s a look at just some of the recent news.
The outbreak of the coronavirus, now called COVID-19, is taking some unexpected twists and turns.
The company’s efforts appear to be working, as it reported fourth-quarter results that exceeded expectations. Company shares popped 9.1% at the news.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name, COVID-19.
A single AQP5+ human gastric stem cell gives rise to a 3D gastric organoid that re-expresses AQP5.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The immuno-oncology therapy, CAR-T, utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged, and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.
The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagnosed 30 hours after birth, apparently having gotten it from the mother.
PRESS RELEASES